indication for cytoreductive therapy in et and pv: do we have it right?
Published 9 years ago • 2.7K plays • Length 17:02Download video MP4
Download video MP3
Similar videos
-
19:02
prognostication and initiation of therapy in polycythemia vera: do we have it right?
-
22:40
treatment goals in essential thrombocythemia and polycythemia vera
-
12:24
development of long-acting interferon as new therapy for pv and et
-
17:25
molecular prognostication in essential thrombocythemia and polycythemia vera: does it matter?
-
16:04
which cytoreductive therapy before transplant for mds?
-
17:25
case study: inadequately controlled polycythemia vera (pv)
-
19:36
evolution of the assessment of clinical benefit in polycythemia vera
-
20:15
hydroxyurea intolerance/resistance in polycythemia vera
-
3:17
what are treatment options for essential thrombocythemia (et) & polycythemia vera (pv)?
-
13:59
essential thrombocythemia
-
24:52
combination therapy with jak2 inhibitors in mpn
-
23:14
why is hydroxyurea first line therapy in the us for essential thrombocythemia?
-
23:39
expert perspectives: jak inhibitors for polycythemia vera
-
22:00
update on long-acting interferons for mpn
-
27:23
interactive case: jak inhibitors for the successful management of polycythemia vera
-
21:27
topical challenges in the management of et
-
13:09
long-acting interferon: what is the difference?
-
21:43
hydroxyurea intolerance/resistance in polycythemia vera
-
20:53
debate: position of jak2 inhibitors as second line therapy in polycythemia vera